ARK Genomic Revolution ETF vs Select Medical Holdings Corporation — how do they compare? ARK Genomic Revolution ETF trades at $41.32, while Select Medical Holdings Corporation trades at $16.51 (market cap $2.05B). The key difference: Select Medical Holdings Corporation pays a 1.51% dividend while ARK Genomic Revolution ETF pays none. Which is the better fit depends on your goals.
| ARKG | SEM | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $43.57 | $16.66 |
52-Week Low | $23.09 | $11.77 |
Market Cap | — | $2.05B |
Enterprise Value | — | $5.01B |
Dividend Yield | — | 1.51% |
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Select Medical Holdings (SEM) trades at $16.51, unchanged on the day, following the company's recent acquisition by a consortium led by Robert A. Ortenzio at $16.50 per share. The stock shows mixed technical signals with a bullish overall trend but bearish moving averages. Fundamentally, the company reported $5.45B revenue for 2025 with a 2.42% net margin, while valuation metrics appear reasonable with a P/E of 15.43 and P/S of 0.36. Recent earnings have been mixed with one beat and two misses against expectations.
The investment outlook is dominated by the completed acquisition, effectively capping upside near the current price. While fundamentals show stable operations with positive cash flow from operations, multiple law firms are investigating potential fiduciary breaches in the buyout process. Analyst sentiment is mixed with 35.7% buy ratings, but the acquisition removes typical growth catalysts. Key risks include legal challenges to the merger terms and execution risks during the ownership transition.
Trailing returns across standard periods
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →Select Medical Holdings Corporation is one of the largest operators of critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational health centers in the United States. The company's services focus on treating patients with serious illnesses, injuries, and post-acute care needs. SEM provides specialized care across various settings, aiming to help patients recover and return home.
Read more on SEM →